Navigation Links
Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
Date:7/15/2008

SOMERSET, N.J., July 15 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that it has entered into a distribution agreement with Megapharm Ltd., a leading pharmaceutical company in Israel, for the commercialization of ONCONASE(R) (ranpirnase) in Israel. ONCONASE, the company's lead drug candidate, recently completed an international confirmatory Phase IIIb clinical trial for unresectable malignant mesothelioma (UMM).

Under the agreement, Alfacell has granted Megapharm exclusive rights in the defined territory for the marketing, sales and distribution of ONCONASE. Alfacell will receive 50% of all sales in the territory. In addition, Alfacell will manufacture and supply the product to Megapharm, while Megapharm will be responsible for all activities and costs related to regulatory filings and commercial activities in the territory.

Miron Drucker, CEO and founder of Megapharm, said, "Having been interested observers in the development of ONCONASE, a first-in-class anti-cancer agent, we are proud to include this unique product in our oncology portfolio. We believe that ONCONASE will prove to be a promising new treatment option for patients suffering from mesothelioma."

"We are very pleased to add Megapharm to our growing list of important regional partners for ONCONASE," said Kuslima Shogen, chief executive officer of Alfacell. "Megapharm's role as a leader in biotechnology marketing in Israel provides Alfacell with an ideal partner to maximize the potential of ONCONASE in this region. We look forward to a successful collaboration with Megapharm."

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) techn
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
7. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...PARK,Md.,Nov.25/PRNewswire-USNewswire/--RemediumTe...efoamthatstopsseverebleeding,wonfirstprizeand$10,0...lSecurityChallenge2009,companyofficialsannouncetod...theworld,Remedium,steampitchedtheirinventionattheG...usiness. ,, Remedium( www.remediumtechnologies....
(Date:11/25/2009)...China,Nov.25/PRNewswire-Asia-FirstCall/--ChinaSkyO...)(Nasdaq: CSKI ),a,leadingfullyintegratedpharmaceu...rdrugsinthePeople,sRepublicofChina("PRC"),today,an...nalInstitutefor,theControlofPharmaceuticalandBiolo...oducts:itsDiagnosticKitforHumanProstateSpecific,An...
(Date:11/25/2009)...TY,Calif.,Nov.25/PRNewswire-FirstCall/--Abaxis,Inc...ingpoint-of-carebloodanalysissystems,announcedtoda...r,willpresentatthe21stAnnualPiperJaffrayHealthCare...heconferencewillbeheldattheNewYorkPalaceHotelinNew...,manufacturesandmarketsportablebloodanalysissystem...
Breaking Medicine Technology:Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Treating Workers Mental Woes May Boost Productivity 56746 1Treating Workers Mental Woes May Boost Productivity 56746 2Wings of Mercy Benefit Features Miracle on the Hudson Heroes 56743 1Wings of Mercy Benefit Features Miracle on the Hudson Heroes 56743 2Wings of Mercy Benefit Features Miracle on the Hudson Heroes 56743 3QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena 28TM 29 28Ospemifene Tablets 29 in Treatment of Postmenopausal 56740 1QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena 28TM 29 28Ospemifene Tablets 29 in Treatment of Postmenopausal 56740 2QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena 28TM 29 28Ospemifene Tablets 29 in Treatment of Postmenopausal 56740 3QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena 28TM 29 28Ospemifene Tablets 29 in Treatment of Postmenopausal 56740 4
... GlaxoSmithKline (NYSE: GSK ),announced positive...d placebo-,controlled ITP Study with Eltrombopag),... adults with chronic immune (idiopathic) thrombocy... prior ITP therapies. Patients,receiving PROMACTA ... to,maintain platelet counts between 50,000 to 400...
...Bayer HealthCare Pharmaceuticals Inc. announced to...ine(R) (sargramostim) will be presented at the 50t...logy (ASH) from December 6-9, 2008 in San Francisc...m leading oncology and hematology research centers... presentations reporting important findings in leu...
Other Medicine Technology:GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 2GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 3GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 4GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 5GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 6GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 7GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP 8Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 2Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 3Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 4Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 5Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology 6
(Date:11/25/2009)...re/--TheBlackAIDSInstituterecentlyheldBoardofDirec... ,, ThenewBoardMembersareahighlydiversegroupofl...vernmenthealthprograms,editorial,andbusinessentrep...albackgroundsincludingbothheterosexualandgayBlackm...tingmultipleagegroups. ,, (Photo: http://www.ne...
(Date:11/25/2009)...o were treated with cisplatin-based chemotherapy h...l side effects and Raynaud-like phenomena, than me...g to a new study published online November 25 in t... Marianne Brydy, M.D., of the Department of Oncolo...ay, and colleagues conducted a cross-sectional stu...
(Date:11/25/2009)...simple question has been the focus of intense rese...lates High Blood Pressure in Mice & Men, Does str... has been the focus of intense research for many y...ablished a link between a novel gene, phosducin, a...s well as humans. The studies were directed by sci...
(Date:11/25/2009)...tment clinics to resume Monday, Nov. 30 , ...09 -- Centegra Health System is continuing to offe...ur Centegra Primary Care (CPC) vaccination clinics...e clinics are at CPC sites in Huntley, Woodstock, ...ws: ,   From 4:30 to 7:30 p.m. Tuesday...
(Date:11/25/2009)...trouble with the H1N1 vaccine, , , WEDN...1 swine flu pandemic may be driving a recent spike... U.S. health official said Wednesday. , "We are...ions around the country," Dr. Anne Schuchat, direc...spiratory Diseases at the U.S. Centers for Disease...
Breaking Medicine News(10 mins):Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4
... Sir Speedy Whittier one of the nation,s p...tions, and Zultys Inc. a leader in corporate Uni...advanced Unified Communications deployment that re... solution provided the features and functions that...
...LA,s Jonsson Comprehensive Cancer Center have deve...ew genes that can predict a predisposition to canc... Radiation Research , was done in yeast and mamma... on that genetic instability. If they can uncover ...
...March 25 Health Robotics today announced,the earl...ATION Profile,option with a presentation [P13] at ...logies Conference and Exhibition (DUPHAT), http://...at no additional cost] was originally,scheduled to...
...t benefits from cutting-edge treatment , , MACO...lled to welcome her twin sons Dawson and Dakota in...to concern when she noticed that over time Dawson,...osition in an infant carrier or crib. , , Ter...
...ch 25 Dr. Bindeshwar Pathak, founder of,Sulabh Sa...9 Stockholm Water,Prize Laureate. , To view th...ww.prnewswire.com/mnr/siwi/37595/ , As the Fo...o improve public health, advance social progress, ...
... Effect Ensures Maximum Value from Pharmacy Progra... Gorman Health Group announced a joint offering to...mprehensive drug benefit oversight. Gorman Health...ce and financial services to offer a comprehensive...
Other Medicine News:Health News:Sir Speedy Whittier and Zultys Announce Advanced Unified Communications Deployment -- Zultys Solution Boosts Responsiveness, Cuts Costs 2Health News:Sir Speedy Whittier and Zultys Announce Advanced Unified Communications Deployment -- Zultys Solution Boosts Responsiveness, Cuts Costs 3Health News:Sir Speedy Whittier and Zultys Announce Advanced Unified Communications Deployment -- Zultys Solution Boosts Responsiveness, Cuts Costs 4Health News:Discovery may result in new test to determine predisposition to cancer 2Health News:Discovery may result in new test to determine predisposition to cancer 3Health News:Health Robotics Announces the Early Release of the i.v.STATION(TM) Profile Option and DUPHAT Presentation 2Health News:Health Robotics Announces the Early Release of the i.v.STATION(TM) Profile Option and DUPHAT Presentation 3Health News:STARscanner, STARband Cranial Helmets Making a Difference in the Lives of Children 2Health News:STARscanner, STARband Cranial Helmets Making a Difference in the Lives of Children 3Health News:Indian Sanitation Innovator and Social Reformer Awarded 2009 Stockholm Water Prize 2Health News:TRICAST, Inc. and Gorman Health Group Form Partnership to Fully Support Medicare Part D Oversight 2Health News:TRICAST, Inc. and Gorman Health Group Form Partnership to Fully Support Medicare Part D Oversight 3
Large Solid Mallet
Hoke Chisel
Chisels
Lewin Bone Forceps
Medicine Products: